The Trump administration has taken steps to partially reschedule cannabis products, moving certain marijuana-based items from the most restrictive federal drug classification to a lower tier.

Acting Attorney General Todd Blanche signed an order last week that reclassifies products sold under state medical cannabis licenses and FDA-approved cannabis products from Schedule I to Schedule III. Schedule I substances are defined as having no accepted medical use, while Schedule III includes legal but regulated substances such as certain doses of Tylenol with codeine and ketamine.

The move represents a partial fulfillment of the administration's campaign promise to reschedule cannabis at the federal level. However, the limited scope of the reclassification has generated questions within the cannabis industry about which products are affected and how the change will be implemented.

Experts have noted that the partial rescheduling creates additional complexity in an already intricate regulatory framework. The order specifically targets state-licensed medical cannabis products and those that have received FDA approval, while leaving other cannabis products in the Schedule I category.

The reclassification could have significant implications for research, banking, and taxation issues that have long affected the cannabis industry, though the full impact of the partial approach remains unclear as stakeholders work to understand the new regulatory landscape.